

Alok A Khorana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6945418/publications.pdf>

Version: 2024-02-01

271
papers

24,599
citations

12330

69
h-index

7348

152
g-index

276
all docs

276
docs citations

276
times ranked

16412
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Vascular Imaging in the Asymptomatic <sc>High-risk</sc> Cancer Population. Journal of Ultrasound in Medicine, 2022, 41, 225-236. | 1.7 | 1 |
| 2 | Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. Blood Advances, 2022, 6, 1212-1221. | 5.2 | 9 |
| 3 | Cancer-associated venous thromboembolism. Nature Reviews Disease Primers, 2022, 8, 11. | 30.5 | 130 |
| 4 | Acellular mucin in lymph nodes isolated from treatment-naïve colorectal cancer resections: a clinicopathologic analysis of 16 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , . | 2.8 | 0 |
| 5 | Building a CAT clinic - real-world systems approaches to prevention and treatment. Thrombosis Research, 2022, 213, S84-S86. | 1.7 | 0 |
| 6 | Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy. Thrombosis Research, 2022, 213, S51-S57. | 1.7 | 6 |
| 7 | Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH-ASCC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927. | 3.8 | 3 |
| 8 | Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score. IJC Heart and Vasculature, 2022, 41, 101072. | 1.1 | 5 |
| 9 | 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347. | 10.7 | 138 |
| 10 | Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12744. | 2.3 | 4 |
| 11 | Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood, 2021, 137, 2103-2113. | 1.4 | 57 |
| 12 | Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist, 2021, 26, e2-e7. | 3.7 | 33 |
| 13 | Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 822-829. | 3.8 | 37 |
| 14 | Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. , 2021, 9, e001719. | | 62 |
| 15 | American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Advances, 2021, 5, 927-974. | 5.2 | 431 |
| 16 | Similarities and perspectives on the two “Cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 1161-1167. | 3.8 | 10 |
| 17 | Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis. Blood Advances, 2021, 5, 2055-2062. | 5.2 | 8 |
| 18 | Increased incidence of venous thromboembolism with cancer immunotherapy. Med, 2021, 2, 423-434.e3. | 4.4 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Venous and Arterial Thromboembolism in Patients With Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 173-190. | 4.0 | 67 |
| 20 | Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , 2021, 11, 121. | 6.2 | 6 |
| 21 | Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12549. | 2.3 | 9 |
| 22 | Future of Personalized Multimodality Management of Locally Advanced Rectal Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 403-404. | 2.9 | 0 |
| 23 | Risk Assessment for Cancer-Associated VTE. <i>JACC Asia</i> , 2021, 1, 271-273. | 1.5 | 2 |
| 24 | Thrombotic Complications Associated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 4606. | 3.7 | 22 |
| 25 | Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. <i>Blood Advances</i> , 2021, 5, 4741-4751. | 5.2 | 16 |
| 26 | Healthcare costs of patients with cancer stratified by Khorana score risk levels. <i>Journal of Medical Economics</i> , 2021, 24, 866-873. | 2.1 | 1 |
| 27 | Racial disparities negatively impact outcomes in early-onset colorectal cancer independent of socioeconomic status. <i>Cancer Medicine</i> , 2021, 10, 7542-7550. | 2.8 | 22 |
| 28 | Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. <i>Targeted Oncology</i> , 2021, 16, 813-821. | 3.6 | 10 |
| 29 | Risk of Venous Thromboembolism in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Blood</i> , 2021, 138, 3223-3223. | 1.4 | 0 |
| 30 | Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome. <i>Blood</i> , 2021, 138, 2117-2117. | 1.4 | 1 |
| 31 | Risk of Venous Thromboembolism and Survival Outcomes in Patients with Lymphoma. <i>Blood</i> , 2021, 138, 4262-4262. | 1.4 | 0 |
| 32 | Publisher note. <i>Thrombosis Research</i> , 2021, 208, 173-175. | 1.7 | 2 |
| 33 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520. | 1.6 | 971 |
| 34 | Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Haematologica</i> , 2020, 105, 1436-1442. | 3.5 | 19 |
| 35 | Rethinking the approach to thrombosis in patients with cancer. <i>Vascular Medicine</i> , 2020, 25, 208-209. | 1.5 | 2 |
| 36 | Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 162-168. | 3.8 | 55 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650. | 4.1 | 28 |
| 38 | Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 651-659. | 3.8 | 19 |
| 39 | Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer. <i>Journal of Medical Economics</i> , 2020, 23, 323-329. | 2.1 | 8 |
| 40 | Evolving Treatment Options for Cancer-Related Venous Thromboembolism. <i>JACC: CardioOncology</i> , 2020, 2, 441-442. | 4.0 | 4 |
| 41 | Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020, 9, 6196-6204. | 2.8 | 20 |
| 42 | Prevention of venous thromboembolism in ambulatory patients with cancer. <i>ESMO Open</i> , 2020, 5, e000948. | 4.5 | 16 |
| 43 | Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525. | 2.9 | 1 |
| 44 | Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. <i>Cancer Medicine</i> , 2020, 9, 8062-8073. | 2.8 | 23 |
| 45 | Preface to the Proceedings of the 10th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2020. <i>Thrombosis Research</i> , 2020, 191, S1-S2. | 1.7 | 0 |
| 46 | Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e914-e931. | 1.6 | 77 |
| 47 | Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , 2020, 4, 2254-2260. | 5.2 | 22 |
| 48 | Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial. <i>TH Open</i> , 2020, 04, e107-e112. | 1.4 | 16 |
| 49 | Mechanisms and biomarkers of cancer-associated thrombosis. <i>Translational Research</i> , 2020, 225, 33-53. | 5.0 | 50 |
| 50 | The guidelines they are a changin'™. <i>European Journal of Internal Medicine</i> , 2020, 74, 5-7. | 2.2 | 0 |
| 51 | RNA expression and risk of venous thromboembolism in lung cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 117-123. | 2.3 | 9 |
| 52 | Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 532-549. | 2.3 | 10 |
| 53 | Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. <i>Cancer</i> , 2020, 126, 1736-1748. | 4.1 | 23 |
| 54 | A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 3047-3060. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Bleeding Outcomes of Gastrointestinal Cancer Patients Treated with Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin. <i>Blood</i> , 2020, 136, 27-27. | 1.4 | 5 |
| 56 | Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project. <i>Blood</i> , 2020, 136, 18-19. | 1.4 | 0 |
| 57 | Risk of Recurrent Venous Thromboembolism and Bleeding in Patients with Cancer Associated Thrombosis. <i>Blood</i> , 2020, 136, 18-18. | 1.4 | 1 |
| 58 | Efficacy and Safety of Tinzaparin in CAT Patients with Metastatic Disease. <i>Blood</i> , 2020, 136, 33-34. | 1.4 | 0 |
| 59 | Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy. <i>Blood</i> , 2020, 136, 8-9. | 1.4 | 0 |
| 60 | Frequency of Arterial Thromboembolic Events in Patients with Cancer Associated Venous Thromboembolism. <i>Blood</i> , 2020, 136, 37-37. | 1.4 | 0 |
| 61 | Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2141-2151. | 3.8 | 41 |
| 62 | Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 629-637. | 2.7 | 8 |
| 63 | Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 454-457. | 2.5 | 7 |
| 64 | The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778. | 3.8 | 107 |
| 65 | Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis. <i>Cancer Treatment and Research</i> , 2019, 179, 55-68. | 0.5 | 3 |
| 66 | Predicting outcomes in patients with cancer and atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986067. | 2.1 | 7 |
| 67 | Modeling Complexity: The Case of Cancer-Related Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1713-1715. | 3.4 | 1 |
| 68 | 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581. | 10.7 | 458 |
| 69 | Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2019, 9, 322-332. | 2.1 | 121 |
| 70 | Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants. <i>Journal of Medical Economics</i> , 2019, 22, 1134-1140. | 2.1 | 12 |
| 71 | Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 2082-2088. | 1.6 | 135 |
| 72 | Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 226-233. | 2.3 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Bleeding incidence and risk factors among cancer patients treated with anticoagulation. American Journal of Hematology, 2019, 94, 780-785. | 4.1 | 92 |
| 74 | Does Sidedness Matter in Unresectable Colorectal Cancer?. Annals of Surgical Oncology, 2019, 26, 1588-1591. | 1.5 | 1 |
| 75 | A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. Oncology, 2019, 96, 217-222. | 1.9 | 14 |
| 76 | Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS ONE, 2019, 14, e0213209. | 2.5 | 179 |
| 77 | Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 153-164. | 1.6 | 135 |
| 78 | If Trousseau had a stroke. Blood, 2019, 133, 769-770. | 1.4 | 2 |
| 79 | Duration of anticoagulant therapy and VTE recurrence in patients with cancer. Supportive Care in Cancer, 2019, 27, 3833-3840. | 2.2 | 9 |
| 80 | Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 720-728. | 27.0 | 520 |
| 81 | The risk of recurrent VTE and major bleeding in a commercially insured population of cancer patients treated with anticoagulation. American Journal of Hematology, 2019, 94, E58-E61. | 4.1 | 10 |
| 82 | Thrombosis and Cancer. , 2019, , 430-447. | | 0 |
| 83 | Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid. Current Oncology Reports, 2019, 21, 18. | 4.0 | 20 |
| 84 | Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.. Journal of Clinical Oncology, 2019, 37, 4016-4016. | 1.6 | 8 |
| 85 | Gastrointestinal Cancers and Thrombosis. , 2019, , 367-378. | | 0 |
| 86 | Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients. Blood, 2019, 134, 3643-3643. | 1.4 | 5 |
| 87 | Clinical Outcomes of Cancer-Associated Thrombosis Beyond 6 Months of Anticoagulation. Blood, 2019, 134, 3458-3458. | 1.4 | 5 |
| 88 | Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism—Analysis of the CATCH Study. Thrombosis and Haemostasis, 2018, 118, 914-921. | 3.4 | 37 |
| 89 | Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1246-1249. | 3.8 | 140 |
| 90 | Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. Oncologist, 2018, 23, 822-839. | 3.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. <i>American Journal of Hematology</i> , 2018, 93, 664-671. | 4.1 | 70 |
| 92 | Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. <i>Thrombosis Research</i> , 2018, 164, S70-S76. | 1.7 | 53 |
| 93 | Multidisciplinary Conference and Clinical Management of Rectal Cancer. <i>Journal of the American College of Surgeons</i> , 2018, 226, 874-880. | 0.5 | 21 |
| 94 | Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. <i>Thrombosis and Haemostasis</i> , 2018, 118, S23-S33. | 3.4 | 12 |
| 95 | Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 40-46.e7. | 1.2 | 95 |
| 96 | Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018, 23, 247-255. | 3.7 | 63 |
| 97 | Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 2326-2347. | 1.6 | 958 |
| 98 | Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2545-2556. | 1.6 | 204 |
| 99 | Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-11. | 3.0 | 6 |
| 100 | Artificial intelligence for cancer-associated thrombosis risk assessment – Author's reply. <i>Lancet Haematology</i> , 2018, 5, e391-e392. | 4.6 | 5 |
| 101 | Adjuvant Treatment in Potentially Curable Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, e50-e52. | 1.1 | 4 |
| 102 | Prevalence of venous thromboembolism diagnosed in emergency department visits by cancer patients and associated healthcare resource utilization in the United States. <i>American Journal of Hematology</i> , 2018, 93, E207. | 4.1 | 1 |
| 103 | Do patients with pancreatic body or tail cancer benefit from adjuvant therapy? A cohort study. <i>Surgical Oncology</i> , 2018, 27, 245-250. | 1.6 | 6 |
| 104 | Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1891-1894. | 3.8 | 325 |
| 105 | Simplicity versus complexity: an existential dilemma as risk tools evolve. <i>Lancet Haematology</i> , 2018, 5, e273-e274. | 4.6 | 14 |
| 106 | Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 664-669. | 2.3 | 47 |
| 107 | Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1. | 1.4 | 12 |
| 108 | Economic Burden of Venous Thromboembolism in Cancer Patients – a Comparative Analysis between Matched Patients with Cancer with and without a Diagnosis of Venous Thromboembolism. <i>Blood</i> , 2018, 132, 366-366. | 1.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Venous Thromboembolism in Cancer Patients Receiving Immunotherapy. <i>Blood</i> , 2018, 132, 2510-2510. | 1.4 | 22 |
| 110 | Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism. <i>Blood</i> , 2018, 132, 3799-3799. | 1.4 | 1 |
| 111 | An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution". <i>American Journal of Hematology</i> , 2018, 93, E225-E227. | 4.1 | 0 |
| 112 | Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 4835-4835. | 1.4 | 0 |
| 113 | Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95. | 1.7 | 109 |
| 114 | Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. <i>American Journal of Hematology</i> , 2017, 92, 501-507. | 4.1 | 60 |
| 115 | Cancer and Venous Thromboembolic Disease: A Review. <i>Oncologist</i> , 2017, 22, 199-207. | 3.7 | 160 |
| 116 | Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 469-478. | 2.7 | 22 |
| 117 | The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the <sc>SAVE</sc> "ONCO" trial control arm. <i>American Journal of Hematology</i> , 2017, 92, E101-E103. | 4.1 | 7 |
| 118 | Multidisciplinary Clinics for Colorectal Cancer Care Reduces Treatment Time. <i>Clinical Colorectal Cancer</i> , 2017, 16, 366-371. | 2.3 | 27 |
| 119 | Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 14-22. | 2.3 | 109 |
| 120 | Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 2182-2186. | 1.6 | 51 |
| 121 | Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection. <i>Journal of Digestive Diseases</i> , 2017, 18, 642-649. | 1.5 | 7 |
| 122 | Identifying predictors for bleeding in hospitalized cancer patients: A cohort study. <i>Thrombosis Research</i> , 2017, 158, 38-43. | 1.7 | 22 |
| 123 | Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017, 39, 1396-1408. | 2.5 | 6 |
| 124 | Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145. | 3.4 | 53 |
| 125 | American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 598-599. | 0.4 | 15 |
| 126 | Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017, 1, pxx009. | 2.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 388-391. | 2.5 | 19 |
| 128 | Reply to R. Fonseca et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2218-2219. | 1.6 | 0 |
| 129 | Reply to A. Wang-Gillam et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 690-691. | 1.6 | 0 |
| 130 | Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1078-1085. | 1.6 | 60 |
| 131 | Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2324-2328. | 1.6 | 160 |
| 132 | American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2203-2208. | 1.6 | 167 |
| 133 | Innovations in American Society of Clinical Oncology Practice Guideline Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 3213-3220. | 1.6 | 14 |
| 134 | Tinzaparin vs Warfarin for Acute Venous Thromboembolismâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 200. | 7.4 | 0 |
| 135 | Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. <i>Thrombosis Research</i> , 2016, 140, S93-S98. | 1.7 | 26 |
| 136 | Venous thromboembolism following hematopoietic stem cell transplantationâ€”a systematic review and meta-analysis. <i>Annals of Hematology</i> , 2016, 95, 1457-1464. | 1.8 | 48 |
| 137 | Reducing Unplanned Medical Oncology Readmissions by Improving Outpatient Care Transitions: A Process Improvement Project at the Cleveland Clinic. <i>Journal of Oncology Practice</i> , 2016, 12, e594-e602. | 2.5 | 40 |
| 138 | Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience. <i>Thrombosis Research</i> , 2016, 147, 102-103. | 1.7 | 9 |
| 139 | International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2016, 17, e452-e466. | 10.7 | 315 |
| 140 | Molecular characteristics of biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 111-118. | 4.4 | 29 |
| 141 | Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?. <i>Thrombosis Research</i> , 2016, 145, 51-53. | 1.7 | 122 |
| 142 | Enhancing Value for Patients With Cancer: Time to Treatment as a Surrogate for Integrated Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 115-116. | 4.9 | 13 |
| 143 | Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2784-2796. | 1.6 | 267 |
| 144 | Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , 2016, 76, 3671-3675. | 0.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Advances in adjuvant therapy of colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2016, 27, 204-212. | 0.3 | 0 |
| 146 | Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2654-2668. | 1.6 | 292 |
| 147 | Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2541-2556. | 1.6 | 302 |
| 148 | Thromboprophylaxis in Cancer Patients. , 2016, , 97-109. | | 0 |
| 149 | Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. <i>Neuro-Oncology Practice</i> , 2016, 3, 87-96. | 1.6 | 26 |
| 150 | A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867. | 3.7 | 54 |
| 151 | Guidance for the prevention and treatment of cancer-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 81-91. | 2.1 | 169 |
| 152 | Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, . | 6.3 | 70 |
| 153 | Recurrent venous thromboembolism in glioblastoma. <i>Thrombosis Research</i> , 2016, 137, 184-188. | 1.7 | 45 |
| 154 | Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer. <i>Blood</i> , 2016, 128, 1178-1178. | 1.4 | 2 |
| 155 | Predictors of Venous Thromboembolism in Colorectal Cancer: Results from a Global Prospective Study. <i>Blood</i> , 2016, 128, 1422-1422. | 1.4 | 1 |
| 156 | Major Bleeding Events Among Cancer and Non-Cancer Patients Taking Rivaroxaban for Venous Thromboembolism Treatment in a Department of Defense Health System Cohort. <i>Blood</i> , 2016, 128, 1447-1447. | 1.4 | 4 |
| 157 | Duration of anticoagulant therapy and VTE recurrence in patients with cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10112-10112. | 1.6 | 1 |
| 158 | Predicting venous thromboembolism in hospitalized cancer patients: a risk assessment tool.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6598-6598. | 1.6 | 3 |
| 159 | Idarucizumab: the first FDA-approved direct oral anticoagulant reversal agent. <i>Journal of Community and Supportive Oncology</i> , 2016, 14, 6-7. | 0.1 | 0 |
| 160 | The wacky hypercoagulable state of malignancy. <i>Blood</i> , 2015, 126, 430-431. | 1.4 | 7 |
| 161 | A health systems approach to risk stratification. <i>Thrombosis Research</i> , 2015, 136, 1049-1050. | 1.7 | 0 |
| 162 | Laparoscopy mitigates adverse oncological effects of delayed adjuvant chemotherapy for colon cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 493-499. | 2.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. <i>Journal of Clinical Oncology</i> , 2015, 33, 654-656. | 1.6 | 911 |
| 164 | Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. <i>Cancer</i> , 2015, 121, 1779-1784. | 4.1 | 28 |
| 165 | Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 880-883. | 3.8 | 96 |
| 166 | Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 325-326. | 3.8 | 3 |
| 167 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 677. | 7.4 | 530 |
| 168 | Cancer Workup after Unprovoked Clot "Less Is More". <i>New England Journal of Medicine</i> , 2015, 373, 768-769. | 27.0 | 6 |
| 169 | Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 199-214. | 1.5 | 7 |
| 170 | Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis. <i>Blood</i> , 2015, 126, 626-626. | 1.4 | 7 |
| 171 | Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study. <i>Journal of Clinical Oncology</i> , 2015, 33, 9621-9621. | 1.6 | 11 |
| 172 | Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated with Mortality in Patients with Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e94048. | 2.5 | 36 |
| 173 | The Reply. <i>American Journal of Medicine</i> , 2014, 127, e35. | 1.5 | 0 |
| 174 | Risk Assessment for Thrombosis in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 319-324. | 2.7 | 40 |
| 175 | Screening high-risk cancer patients for VTE: A prospective observational study. <i>Thrombosis Research</i> , 2014, 134, 1205-1207. | 1.7 | 39 |
| 176 | Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1746-1749. | 3.8 | 36 |
| 177 | Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju011-dju011. | 6.3 | 141 |
| 178 | Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1792-1796. | 1.6 | 45 |
| 179 | Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. <i>Thrombosis Research</i> , 2014, 134, 1214-1219. | 1.7 | 154 |
| 180 | Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1928-1931. | 3.8 | 55 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. <i>British Journal of Cancer</i> , 2014, 111, 430-436. | 6.4 | 56 |
| 182 | The Reply. <i>American Journal of Medicine</i> , 2014, 127, e13. | 1.5 | 0 |
| 183 | Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer. <i>American Journal of Medicine</i> , 2014, 127, 82-86.e1. | 1.5 | 132 |
| 184 | Risk stratification strategies for cancer-associated thrombosis: an update. <i>Thrombosis Research</i> , 2014, 133, S35-S38. | 1.7 | 93 |
| 185 | Correspondence. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 452-453. | 4.9 | 1 |
| 186 | Decision Time. <i>Annals of Internal Medicine</i> , 2014, 160, 436-437. | 3.9 | 0 |
| 187 | A Randomized Trial of Long-Term Tinzaparin, a Low Molecular Weight Heparin (LMWH), Versus Warfarin for Treatment of Acute Venous Thromboembolism (VTE) in Cancer Patients - the CATCH Study. <i>Blood</i> , 2014, 124, LBA-2-LBA-2. | 1.4 | 15 |
| 188 | CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. <i>BMC Cancer</i> , 2013, 13, 284. | 2.6 | 61 |
| 189 | Targeted prophylaxis in cancer: the evidence accumulates. <i>Internal and Emergency Medicine</i> , 2013, 8, 187-189. | 2.0 | 11 |
| 190 | Prevalence and Clinical Significance of Incidental and Clinically Suspected Venous Thromboembolism in Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2013, 14, 713-718. | 2.6 | 65 |
| 191 | Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1760-1765. | 3.8 | 143 |
| 192 | Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 2189-2204. | 1.6 | 717 |
| 193 | Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. <i>Thrombosis Research</i> , 2013, 132, 180-184. | 1.7 | 111 |
| 194 | International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 56-70. | 3.8 | 469 |
| 195 | International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 71-80. | 3.8 | 252 |
| 196 | Thrombosis and Cancer. , 2013, , 408-422. | | 0 |
| 197 | Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. <i>Cancer</i> , 2013, 119, 648-655. | 4.1 | 356 |
| 198 | Reply to T.H. Oo. <i>Journal of Clinical Oncology</i> , 2013, 31, 4381-4382. | 1.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Venous Thromboembolism Prevention in Cancer Outpatients. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1431-1438. | 4.9 | 17 |
| 200 | Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. ClinicoEconomics and Outcomes Research, 2013, 5, 101. | 1.9 | 107 |
| 201 | Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e337-e345. | 3.8 | 16 |
| 202 | Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e337-e345. | 3.8 | 9 |
| 203 | Can EGFR mutation status evolve with chemotherapy?. Chinese Clinical Oncology, 2013, 2, 1. | 1.2 | 11 |
| 204 | Preventing VTE in Outpatients With Cancer. Chest, 2012, 142, 265-266. | 0.8 | 3 |
| 205 | Risk assessment for cancer-associated thrombosis: What is the best approach?. Thrombosis Research, 2012, 129, S10-S15. | 1.7 | 35 |
| 206 | Diabetes Mellitus Is Associated With the Presence of Metastatic Spread at Disease Presentation in Hepatocellular Carcinoma. Cancer Investigation, 2012, 30, 698-702. | 1.3 | 9 |
| 207 | Incidental venous thromboembolism in oncology patients. Journal of Thrombosis and Haemostasis, 2012, 10, 2602-2604. | 3.8 | 70 |
| 208 | Cancer-associated thrombosis: updates and controversies. Hematology American Society of Hematology Education Program, 2012, 2012, 626-630. | 2.5 | 57 |
| 209 | The use of weighted and scored risk assessment models for venous thromboembolism. Thrombosis and Haemostasis, 2012, 108, 1072-1076. | 3.4 | 40 |
| 210 | Cancer and coagulation. American Journal of Hematology, 2012, 87, S82-7. | 4.1 | 68 |
| 211 | Cancer-associated thrombosis: updates and controversies. Hematology American Society of Hematology Education Program, 2012, 2012, 626-30. | 2.5 | 34 |
| 212 | Cancer-associated thrombosis: an update. Drug Discovery Today Disease Mechanisms, 2011, 8, e39-e45. | 0.8 | 4 |
| 213 | Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thrombosis and Haemostasis, 2011, 106, 371-378. | 3.4 | 124 |
| 214 | Risk Assessment and Prophylaxis for VTE in Cancer Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 789-797. | 4.9 | 37 |
| 215 | Can Literature Enhance Oncology Training? A Pilot Humanities Curriculum. Journal of Clinical Oncology, 2011, 29, 468-471. | 1.6 | 13 |
| 216 | Higher Incidence of Venous Thromboembolism in the Outpatient Versus the Inpatient Setting Among U.S. Cancer Patients. Blood, 2011, 118, 674-674. | 1.4 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Venous Thromboembolism in Patients with Hematologic Malignancies. , 2011, , 449-459. | | 0 |
| 218 | Venous Thromboembolism (VTE) In Hospitalized Patients: What Proportion Is Attributable to Malignancy?. Blood, 2011, 118, 5250-5250. | 1.4 | 2 |
| 219 | The role of thromboprophylaxis in cancer patients: emerging data. Current Opinion in Hematology, 2010, 17, 450-456. | 2.5 | 9 |
| 220 | Physician As Typist. Journal of Clinical Oncology, 2010, 28, 3899-3900. | 1.6 | 11 |
| 221 | Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€œDirected Intergroup Trial S0205. Journal of Clinical Oncology, 2010, 28, 3605-3610. | 1.6 | 570 |
| 222 | A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology, 2010, 78, 125-129. | 1.9 | 17 |
| 223 | A Computerized Prompt for Thromboprophylaxis in Hospitalized Cancer Patients. Thrombosis Research, 2010, 126, 32-34. | 1.7 | 5 |
| 224 | Venous thromboembolism and prognosis in cancer. Thrombosis Research, 2010, 125, 490-493. | 1.7 | 319 |
| 225 | Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thrombosis Research, 2010, 126, 113-118. | 1.7 | 115 |
| 226 | Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thrombosis Research, 2010, 125, S1-S7. | 1.7 | 82 |
| 227 | Cancer Patients and Awareness of Venous Thromboembolism. Cancer Investigation, 2010, 28, 44-45. | 1.3 | 33 |
| 228 | Symptomatic and Incidental Thromboses Are Both Associated with Mortality In Pancreatic Cancer. Blood, 2010, 116, 3167-3167. | 1.4 | 1 |
| 229 | A Predictive Risk Score for Cancer-Associated Thrombosis: Role of Screening In A Prospective Study. Blood, 2010, 116, 3173-3173. | 1.4 | 10 |
| 230 | The role of the oncologist in the management of VTE. Clinical Advances in Hematology and Oncology, 2010, 8, 524-6. | 0.3 | 0 |
| 231 | New Insights Into Cancer-Associated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 316-320. | 2.4 | 70 |
| 232 | Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology, 2009, 27, 4821-4826. | 1.6 | 149 |
| 233 | Cancer and thrombosis: implications of published guidelines for clinical practice. Annals of Oncology, 2009, 20, 1619-1630. | 1.2 | 101 |
| 234 | Risk stratification for cancer-associated venous thromboembolism. Best Practice and Research in Clinical Haematology, 2009, 22, 35-47. | 1.7 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Tissue Factor and VEGF Expression in Prostate Carcinoma: A Tissue Microarray Study. <i>Cancer Investigation</i> , 2009, 27, 430-434. | 1.3 | 18 |
| 236 | Cancer and Thrombosis: Back to the Future<i>Renewed Interest in an Old Problem</i>. <i>Cancer Investigation</i> , 2009, 27, 472-473. | 1.3 | 8 |
| 237 | Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. <i>Thrombosis Research</i> , 2009, 123, S18-S21. | 1.7 | 64 |
| 238 | Assessing Risk of Venous Thromboembolism in the Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4839-4847. | 1.6 | 446 |
| 239 | Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. <i>Journal of Clinical Oncology</i> , 2009, 27, 4919-4926. | 1.6 | 162 |
| 240 | Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. <i>Cancer</i> , 2008, 113, 224-224. | 4.1 | 1 |
| 241 | Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. <i>Thrombosis Research</i> , 2008, 122, 299-306. | 1.7 | 99 |
| 242 | Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. <i>Archives of Internal Medicine</i> , 2008, 168, 2377. | 3.8 | 304 |
| 243 | Disorientation. <i>Health Affairs</i> , 2008, 27, 1154-1159. | 5.2 | 1 |
| 244 | Development and validation of a predictive model for chemotherapy-associated thrombosis. <i>Blood</i> , 2008, 111, 4902-4907. | 1.4 | 1,682 |
| 245 | Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy. <i>Blood</i> , 2008, 112, 172-172. | 1.4 | 9 |
| 246 | Venous Thromboembolism and Anticoagulation. <i>Translational Medicine Series</i> , 2008, , 1-29. | 0.0 | 0 |
| 247 | Ambulatory Patient Preference for VTE Prophylaxis. <i>Blood</i> , 2008, 112, 4709-4709. | 1.4 | 0 |
| 248 | The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients. <i>Oncologist</i> , 2007, 12, 1361-1370. | 3.7 | 116 |
| 249 | Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2870-2875. | 7.0 | 338 |
| 250 | Approaches to risk-stratifying cancer patients for venous thromboembolism. <i>Thrombosis Research</i> , 2007, 120, S41-S50. | 1.7 | 31 |
| 251 | American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5490-5505. | 1.6 | 875 |
| 252 | A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment. <i>Cancer</i> , 2007, 110, 1149-1161. | 4.1 | 198 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 253 | Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. <i>Cancer</i> , 2007, 110, 2339-2346. | 4.1 | 662 |
| 254 | Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. <i>Liver Transplantation</i> , 2007, 13, 807-813. | 2.4 | 64 |
| 255 | Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 632-634. | 3.8 | 1,309 |
| 256 | Venous thromboembolism in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1029-1033. | 1.3 | 80 |
| 257 | FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. <i>Blood</i> , 2006, 107, 126-131. | 1.4 | 82 |
| 258 | Thromboembolism in Hospitalized Neutropenic Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 484-490. | 1.6 | 424 |
| 259 | Vascular Endothelial Growth Factor and Predict Adjuvant Therapy Outcomes in Resected Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 903-911. | 1.7 | 27 |
| 260 | Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. <i>Cancer</i> , 2005, 104, 2822-2829. | 4.1 | 475 |
| 261 | Concordance. <i>Health Affairs</i> , 2005, 24, 511-515. | 5.2 | 3 |
| 262 | The Influence of Host Response on Colorectal Cancer Prognosis. <i>Clinical Colorectal Cancer</i> , 2004, 4, 38-45. | 2.3 | 37 |
| 263 | Pancreatic cancer and thromboembolic disease. <i>Lancet Oncology</i> , The, 2004, 5, 655-663. | 10.7 | 229 |
| 264 | Venous Thromboembolic Events in Patients with Diffuse Large B cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2004, 104, 4542-4542. | 1.4 | 2 |
| 265 | Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma. <i>Cancer</i> , 2003, 97, 960-968. | 4.1 | 147 |
| 266 | Malignancy, thrombosis and Trousseau: the case for an eponym. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2463-2465. | 3.8 | 116 |
| 267 | A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. <i>Cancer Gene Therapy</i> , 2003, 10, 251-259. | 4.6 | 61 |
| 268 | At The End Of A Day. <i>Health Affairs</i> , 2003, 22, 239-243. | 5.2 | 0 |
| 269 | Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2110-2115. | 2.4 | 126 |
| 270 | A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 41, 77-87. | 1.3 | 48 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Author's Reply to Åžener and Begijanashvili: "Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy" Targeted Oncology, 0, , . | 3.6 | 0 |